Use of TGF-.beta..sub.3 to reduce the formation of scar tissue in response to corneal trauma
US5411940A · kind A · utility
8Cited by
8References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 29, 1993 |
| Grant date | May 2, 1995 |
| Priority date | — |
| Expiry date | Sep 29, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/1841
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of TGF-.beta..sub.3 to reduce the formation of scar tissue as a result of trauma to the cornea of the eye is described. The invention is particularly directed to the use of TGF-.beta..sub.3 to reduce the formation of scar tissue in connection with ophthalmic surgical procedures involving the cornea, such as laser irradiation of the cornea. A composition containing TGF-.beta..sub.3 is applied to the site of the trauma to alter the production and composition of extracellular matrix synthesized by fibroblasts, and thereby reduce the formation of scar tissue and consequent impairment of vision.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.